AFP and cancer: This amalgamation may offer a multifaceted approach, leveraging both genetic and protein-level information, providing a more nuanced understanding of tumor dynamics and offering refined risk stratification strategies for personalized patient care in hepatoblastoma and other cancers where AFP and ctDNA play pivotal roles as biomarkers.